Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

15.11.2017 | Brief Report

Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting

verfasst von: Omar Abdel-Rahman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer.

Methods

Surveillance, epidemiology, and end results (SEER) database (2010–2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) according to both anatomical and prognostic stages. Likewise, Cox cause-specific hazard ratio with pairwise hazard ratio comparisons were also assessed for both anatomical and prognostic stages. Survival analyses according to both anatomical and prognostic staging systems were conducted through Kaplan–Meier analysis/log-rank testing.

Results

A total of 209,304 patients with non-metastatic breast cancer and upfront surgical treatment were included. According to anatomical stages, pairwise Cox hazard ratio comparisons between different stages were significant (P < 0.0001) except between stage IIIB and stage IIIC, while according to prognostic stages, all pairwise hazard ratio comparisons between different stages were significant (P < 0.05). Sub-distribution hazard ratio (using breast cancer death as the primary failure endpoint and using other causes of death as competing causes of death) adjusted for age, race, and surgery was as follows: for the anatomical groups, it was 1.671 (95% CI 1.627–1.716; P < 0.0001) indicating increasing risk of death from breast cancer with increasing stage; however, for the prognostic groups it was 1.790 (95% CI 1.744–1.838; P < 0.0001) indicating increasing risk of death from breast cancer with increasing stage. C-statistic was assessed using breast cancer death as the dependent variable; and the findings for the two staging systems were as follows: anatomical staging: 0.767 (SE 0.004; 95% CI 0.759–0.776); prognostic staging: 0.814 (SE 0.004; 95% CI 0.807–0.822).

Conclusions

The current analysis showed an improvement in the discriminatory value for the prognostic staging system compared to the anatomical staging system and endorsed its routine use in clinical practice.
Literatur
2.
Zurück zum Zitat Abdoli G, Bottai M, Sandelin K, Moradi T (2017) Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden. Breast 31:57–65CrossRefPubMed Abdoli G, Bottai M, Sandelin K, Moradi T (2017) Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden. Breast 31:57–65CrossRefPubMed
3.
Zurück zum Zitat Jackisch C, Lammers P, Jacobs I (2017) Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast 32:199–216CrossRefPubMed Jackisch C, Lammers P, Jacobs I (2017) Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast 32:199–216CrossRefPubMed
4.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The eighth edition ajcc cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The eighth edition ajcc cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99CrossRefPubMed
5.
Zurück zum Zitat Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C (2012) Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol 19(9):3028–3034CrossRefPubMed Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C (2012) Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol 19(9):3028–3034CrossRefPubMed
6.
Zurück zum Zitat Amin MB, Edge SB (2017) AJCC cancer staging manual. Springer, New YorkCrossRef Amin MB, Edge SB (2017) AJCC cancer staging manual. Springer, New YorkCrossRef
8.
Zurück zum Zitat Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ et al (2017) Breast cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303CrossRefPubMed Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ et al (2017) Breast cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(4):290–303CrossRefPubMed
9.
Zurück zum Zitat Souza JAd, Hunt B, Asirwa FC, Adebamowo C, Lopes G (2016) Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. J Clin Oncol 34(1):6–13CrossRefPubMed Souza JAd, Hunt B, Asirwa FC, Adebamowo C, Lopes G (2016) Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. J Clin Oncol 34(1):6–13CrossRefPubMed
10.
Zurück zum Zitat Figueroa-Magalhaes MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. Breast 23(2):128–136CrossRefPubMed Figueroa-Magalhaes MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. Breast 23(2):128–136CrossRefPubMed
11.
Zurück zum Zitat Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M et al (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756–2764CrossRefPubMedPubMedCentral Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M et al (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756–2764CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654–4661CrossRefPubMedPubMedCentral Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654–4661CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Abdel-Rahman O (2017) Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. Breast Cancer Res Treat 164(1):231–236CrossRefPubMed Abdel-Rahman O (2017) Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. Breast Cancer Res Treat 164(1):231–236CrossRefPubMed
14.
Zurück zum Zitat Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF et al (2016) The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol 2(7):929–936CrossRefPubMedPubMedCentral Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF et al (2016) The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol 2(7):929–936CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK et al (2017) Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. Ann Surg 265(3):574–580CrossRefPubMed Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK et al (2017) Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. Ann Surg 265(3):574–580CrossRefPubMed
16.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016) West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349CrossRefPubMed Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M et al (2016) West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341–2349CrossRefPubMed
18.
Zurück zum Zitat Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A et al (2015) Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol 26(3):510–516CrossRefPubMed Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A et al (2015) Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol 26(3):510–516CrossRefPubMed
Metadaten
Titel
Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting
verfasst von
Omar Abdel-Rahman
Publikationsdatum
15.11.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4577-x

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.